There is an increasing need for a highly accurate, automated system to enable tight glycemic control and avoid hypoglycemia in hospital Intensive Care Units (ICU). OptiScan Biomedical Corporation, a fast-moving, late stage venture-backed company, is completing development and clinical trials of a glucose monitoring system to provide accurate blood glucose measurements at a wide range of glucose concentrations. The OptiScan system, called the OptiScanner™ Continuous Blood Glucose Monitor Model 5000, measures the infrared absorption of glucose in plasma, using a very small sample of blood, approximately 150 µL per measurement cycle. OptiScan currently estimate the size of this medical device market to be approximately $6 billion.
21021 Corsair Boulevard